Dapagliflozin Performance In Phase III Leaves Concerns,Particularly About Urinary Infections
This article was originally published in Pharmaceutical Approvals Monthly
Phase III results for Bristol-Myers Squibb/AstraZeneca’s dapagliflozin released at the 2010 American Diabetes Association meeting are raising questions about whether the SGLT-2 inhibitor and others like it have a chance at competing for a second-line role against DPP-4 inhibitors, despite worrisome urinary infection side effects.
You may also be interested in...
Five Phase III trials presented at ADA show J&J’s canagliflozin improves glycemic control over existing treatments and could offer a weight loss benefit to diabetes patients; they are part of a nine-study package that J&J submitted to FDA for approval May 31.
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting